Major changes from 2017 ELN include the addition of seven myelodysplasia-related mutations to the adverse group (in the absence of favorable-risk markers); placing NPM1-mutated patients with adverse-risk cytogenetic abnormalities in the adverse group; consideration of only the presence, not allelic ratio, of FLT3-ITD; and the substitution of biallelic CEBPA mutations with in-frame mutations affecting the basic leucine zipper (bZIP) region of the CEBPA gene (CEBPAbZIP) as favorable-risk markers. This evidence concerns the gene FLT3 and Myelodysplasia.